GPR35, a recently deorphanized GPCR, has garnered attention as a potential therapeutic target due to its associations with various pathologies, including heart failure (Divorty et al. 2018; Ronkainen et al. 2014), diabetes (Horikawa et al. 2000) and inflammatory diseases (Farooq et al. 2018). This evidence concerns the gene GPR35 and diabetes mellitus.